Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2006;332:569 (11 March), doi:10.1136/bmj.332.7541.569
New York Janice Tanne
Subsidies for combination treatments in countries where malaria is endemic are urgently needed to forestall drug resistance and save lives, warns a paper published this week.
A subsidy of only $100m (£57m; €83m) to $200m for artemisinin based combination drugs might be needed, said Ramanan Laxminarayan, from Resources for the Future, a non-profit, independent organisation based in Washington, DC, and the paper’s lead author.
He said that if such a subsidy programme was implemented within three months, up to 25 000 lives a month could be saved (Health Affairs 2006;25:325-36).
Dr Laxminarayan, whose coauthors are from the World Bank and the US National Institutes of Health, said, “Providing the subsidies is probably the most important thing the world can do for malaria today. I can’t think of another public health program that could be deployed so rapidly and would save as many lives. One and a
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?